These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3067652)

  • 1. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease.
    Wooten GF
    Ann Neurol; 1988 Sep; 24(3):363-5. PubMed ID: 3067652
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 8. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD
    Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
    [No Abstract]   [Full Text] [Related]  

  • 12. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 14. [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
    Stocchi F; Ruggieri S; Baronti F; Bellantuono P; Brughita G; Antonini A; Bravi D; Agnoli A
    Clin Ter; 1987 Jul; 122(2):83-8. PubMed ID: 2973904
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications and limitations of drug therapy for Parkinson's disease.
    Jankovic J
    Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 18. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives in the treatment of Parkinson's disease.
    LeWitt PA
    Clin Neuropharmacol; 1986; 9 Suppl 1():S37-54. PubMed ID: 3085929
    [No Abstract]   [Full Text] [Related]  

  • 20. Levodopa: rational and irrational pharmacology.
    Nutt JG
    Ann Neurol; 1994 Jul; 36(1):4-5. PubMed ID: 8024259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.